At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 29, 2026 at 14:00 ET
MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient population for the company's inhaled insulin product, a significant label expansion for a single-product biotech with a $1.1B market cap. The stock has a history of high volatility on news events.
- FDA approved Afrezza for use in children and adolescents aged 6+ with diabetes
- This is a label expansion for MannKind's sole marketed product, Afrezza
- Company has a $1.1B market cap, early-stage biotech dynamics apply
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access